This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Circulation, Vol 80, 1544-1548, Copyright © 1989 by American Heart Association

ARTICLES

Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. PACK Claudication Substudy

The effect of ketanserin on intermittent claudication (measured by treadmill walking distance and ankle systolic pressure) was assessed in 594 patients, a subset of the 3,899 patients who composed a double- blind study of the effect of ketanserin on cardiovascular events. Complete data sets at the beginning and end of 1 year's treatment with ketanserin or placebo were available in 436 patients. There was no difference between the groups in the improvement in pain-free treadmill walking distance. The placebo effect on treadmill walking distance increased continuously for at least 1 year at the rate of about 15% every 6 months. There was no significant change in either group in the ankle systolic pressure at the end of the treatment period but in the group given ketanserin, brachial systolic pressure was decreased and the ankle to arm systolic pressure ratio therefore increased. There was only a very weak association between treadmill walking distance and ankle to arm systolic pressure ratio both at the beginning and in terms of change over 1 year. Therefore, this pressure ratio is probably not a useful way of assessing the effects of medical treatment of claudication.

This article has been cited by other articles:

				M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]

				L Norgren, A Jawien, L Matyas, H Rieger, K Arita, and European MCI-9042 Study Group Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study Vascular Medicine, May 1, 2006; 11(2): 75 - 83. [Abstract] [PDF]

				G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 609S - 626S. [Abstract] [Full Text] [PDF]

				H. Bounameaux Intermittent claudication: how should we react to this symptom? Eur. Heart J., July 1, 2002; 23(13): 1002 - 1004. [Full Text] [PDF]

				M. R. Jackson and G. P. Clagett Antithrombotic Therapy in Peripheral Arterial Occlusive Disease Chest, January 1, 2001; 119 (2009): 283S - 299S. [Full Text] [PDF]

				J. I. Weitz, J. Byrne, G. P. Clagett, M. E. Farkouh, J. M. Porter, D. L. Sackett, D. E. Strandness, and L. M. Taylor Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review Circulation, December 1, 1996; 94(11): 3026 - 3049. [Full Text]

				J. P Cooke and M. A Creager Management of the patient with intermittent claudication Vascular Medicine, March 1, 1991; 2(1): 19 - 31. [PDF]